| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8220055 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 7 Pages |
Abstract
This regimen was well tolerated. The gemcitabine MTD was 25 mg/m². Bladder preservation and disease control were promising. A multicenter phase 2 randomized trial is ongoing.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
David MD, PhD, Olivier MD, Xavier MD, Simon MSc, Rodolphe MD, PhD, Pascal MSc, Damien MD, Stephane MD, PhD,